Dr. KSS MD PhD, author of this article, says:
December 9, 2015 at 10:44 am
Honor Roll Post of the Day!
To give a little insight on the situation, what I feel has happened is that they have advanced enough to sufficiently high doses of TT-034 such that they are in what should be therapeutic range…..and are seeing no effect on patient HCV RNA viral burden. Accordingly, French has bum-steered them. They have languished two years in but one clinical project and it is a bust. Oh, and French would have loved a gig as a US CEO. The board turned against him. They had to. With what’s been gained in knowledge, moreover, in the new HBV race, I think heads wiser than French’s are realizing that a ddRNAi therapeutic alone against HBV has almost no chance of working.
With correct inclusion of clinicians early in their planning, and with a genuine CEO with CEO qualities, this could have been a royally hot superstar biotech. Now, however, I cannot see them even being extant in 2017 and beyond.
- Forums
- ASX - By Stock
- BLT
- BLT.AX says CEO and Managing Director Dr Peter French Resigned
BLT.AX says CEO and Managing Director Dr Peter French Resigned, page-36
-
- There are more pages in this discussion • 79 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
FWD
Queensland's housing crisis an opportunity for ASX builder Fleetwood – and taxpayer cash a safe harbour from the storm